Metals and Mining
Company Overview of Ansell Capital Corp.
As of November 27, 2014, Ansell Capital Corp. was acquired by BriaCell Therapeutics Corp., in a reverse merger transaction. Ansell Capital Corp. Prior To Reverse Merger With BriaCell Therapeutics Corp. acquires, explores, and develops mineral properties. It primarily explores for gold, silver, copper, and other metals. The company holds interests in the Kuyakuz Mountain project located in British Columbia, Canada; and the Charlotte property located in the Yukon Territory, Canada. It also holds an option agreement to acquire a 100% interest in the Dal, the Discovery Creek, and the Etzel properties located in the Yukon Territory, Canada. The company was incorporated in 2006 and is based in Wes...
West Vancouver, BC V7T 2X1
Founded in 2006
Key Executives for Ansell Capital Corp.
Ansell Capital Corp. does not have any Key Executives recorded.
Ansell Capital Corp. Key Developments
Ansell Capital Corp. Announces Board Appointments
Dec 1 14
On November 25, 2014, Ansell Capital Corp. filed a Notice of Alteration with the Registrar of Companies of the Province of British Columbia to change its corporate name from "Ansell Capital Corp." to "BriaCell Therapeutics Corp." The name change followed a 3.25 to 1 share consolidation both of which were approved at the company's Annual General and Special Meeting held on the same date. The name change was approved and the company's proposed nominees, Rahoul Sharan, and new directors, Dr. Charles Wiseman, Dr. Saeid Babei and Isaac B. Maresky were all appointed to the Board.
Ansell Capital Corp. Auditor Raises 'Going Concern' Doubt
Oct 23 14
Ansell Capital Corp. filed its Annual on Oct 23, 2014 for the period ending Jul 31, 2014. In this report its auditor, Davidson & Company, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Ansell Capital Corp., Special/Extraordinary Shareholders Meeting, Nov 25, 2014
Sep 26 14
Ansell Capital Corp., Special/Extraordinary Shareholders Meeting, Nov 25, 2014., at 10:30 Pacific Standard Time. Location: 217-179 Davie Street. Agenda: To consider and approve a consolidation of the issued and outstanding common shares of Ansell on a 3.25-old for 1- new basis as part of Ansell's proposed acquisition of BriaCell Therapeutics Corp.; to consider and authorize Ansell to acquire all of the issued and outstanding shares of BriaCell Therapeutics Corp. for and in consideration 53,111,568 post-consolidated common shares of Ansell giving rise to a change of business and reverse takeover of Ansell with the share consideration to be issued subject to Value Securities escrow conditions; to authorize Ansell to change its name to "BriaCell Therapeutics Corp.", or such other name as the board of directors of Ansell may determine to be acted upon concurrently with Ansell's acquisition of BriaCell; and to receive the report of the directors, the audited financial statements of Ansell for the period ended July 31, 2014, and the report of the auditors thereon.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|